Non Hodgkin Lymphoma Clinical Trial
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment.
This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab Vedotin for sale in the United States for certain diseases. Brentuximab is still being studied in clinical trials like this one to learn more about what its side effects are and whether or not it is effective in the disease or condition being studied.
Brentuximab Vedotin is a type of drug called an antibody drug conjugate (ADC). ADCs usually have 2 parts; a part that targets cancer cells (the antibody) and a cell killing part (the chemotherapy). Antibodies are proteins that are part of your immune system. They can stick to and attack specific targets on cells. The antibody part of Brentuximab Vedotin sticks to a target called CD30. CD30 is an important molecule on some cancer cells (including non Hodgkin lymphoma) and some normal cells of the immune system. The cell killing part of Brentuximab Vedotin is a chemotherapy called monomethyl auristatin E (MMAE). It can kill cells that the antibody part of Brentuximab Vedotin sticks to. Brentuximab Vedotin has also been shown to kill cancer cells with levels of CD30 that cannot be seen by traditional methods.
This study is being done to test if the study drug has an effect on Mature T cell Lymphoma with such low levels of a target called CD30 and how your disease respond to the study drug.
• To determine overall response rate (CR+PR) of brentuximab vedotin in CD30 low (<10%) relapsed or refractory T cell lymphoma (TCL)
Complete remission (CR) rate
Duration of response (DOR)
Progression free survival (PFS)
Overall survival (OS)
Time to treatment failure (TTF)
Patients must have histologically or cytologically confirmed relapsed/refractory CD30 low (<10%) TCL: including peripheral TCL not otherwise specified (PTCL NOS), angioimmunoblastic T cell lymphoma (AITL), hepato-splenic T cell lymphoma (HTCL), adult T cell leukemia/lymphoma (ATLL), enteropathy associated T cell lymphoma (EATL), adult T cell leukemia/lymphoma (ATLL), enteropathy associated T cell lymphoma (EATL), NK T cell lymphoma (NK/TCL)
At least 1 prior chemotherapy regimen
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. ECOG Performance Status (PS) 3 will be permitted if the decreased PS is attributed to the lymphoma
Adequate organ function
Bilirubin ≤1.5X upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3X ULN even in patients with documented hepatic involvement with lymphoma
Serum creatinine clearance ≥30 ml/min
Absolute neutrophil count (ANC) ≥1000/μL (unless documented bone marrow involvement with lymphoma)
Platelet count ≥50,000/μL (unless documented bone marrow involvement with lymphoma)
At least 6 weeks from autologous stem cell transplantation
At least 3 months from allogeneic stem cell transplantation and off immunosuppression and no evidence of graft versus host disease (GVHD)
Previous treatment with brentuximab vedotin will be allowed if it was done 6 months prior to enrollment and patient was not refractory
Measurable disease ≥1.5 cm seen on computed tomography (CT) scan and Fluorodeoxyglucose (FDG) avid disease on positron emission Tomography (PET) scan. Splenomegaly measuring >12 cm, if attributed to TCL and/or positive bone marrow involvement with lymphoma are also eligible.
Females of childbearing potential must have a negative serum or urine pregnancy test result within 7 days prior to the first dose of study treatment. Women of child-bearing age must agree to use an effective contraception method during the study and for at least 6 months following the last dose of study drug.
Males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 6 months following the last dose of study drug.
Subjects must have the ability to understand and the willingness to sign a written informed consent document
Anaplastic large cell lymphoma (ALCL) both alk positive and negative
Cutaneous T cell lymphomas except transformed Mycosis fungoides (MF)
Prior treatment with Brentuximab in the last 6 months or previously refractory to Brentuximab Vedotin (BV) or had progressive disease (PD) while on BV
Pregnancy or breast feeding women
Prior malignancy within the past 3 years except non melanoma skin cancer or other localized cancer treated with curative intent
Presence of grade >2 peripheral neuropathy or patients with the demyelinating form of Charcot-Marie-Tooth syndrome.
Presence of central nervous system (CNS) involvement requiring active treatment
History of progressive multifocal leukoencephalopathy (PML)
Myocardial infarction within the past 6 months
Patients with the following medical conditions that could affect their participation in the study:
any active acute or chronic or uncontrolled infection
liver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitis
a known history of HIV
symptomatic cardiac disease, including congestive heart failure, coronary artery disease, and arrhythmias
Prior hypersensitivity to any component in the ADC formulation
Treatment with chemotherapy or investigational agents within 2 weeks of start of study treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Ann Arbor Michigan, 48109, United States
Detroit Michigan, 48201, United States More Info
Hackensack New Jersey, 07601, United States
Cleveland Ohio, 44106, United States
Cleveland Ohio, 44195, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.